Conditions: Coronary Artery Disease
Keywords: CAD
Allocation: RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: no

Brief summary:
To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.

Detailed description:

Arms:
arm 1: Cangrelor IV + Oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation arm 2: Prasugrel discontinued 48h (n=6) prior to initiation of cangrelor infusion (2h) arm 3: Cangrelor IV + oral prasugrel (60mg) administered at 1.5h after the cangrelor infusion start time. arm 4: Cangrelor IV + oral prasugrel (60mg) administered at 1.0h after the cangrelor infusion start time. arm 5: Prasugrel discontinued 24h prior to initiation of cangrelor infusion (2h)

Interventions: intervention 1: Cangrelor intervention 2: Prasugrel
Intervention descriptions: intervention 1: Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8 intervention 2: Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.

Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8.

Protocol document: